Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 391

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L, RSV 6120/ΔNS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

Condition:   Respiratory Syncytial Virus (RSV)
Interventions:   Biological: RSV ΔNS2/Δ1313/I1314L Vaccine;   Biological: RSV 6120/ΔNS2/1030s Vaccine;   Biological: RSV 276 Vaccine;   Biological: Placebo
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting
ClinicalTrials.gov: Infections_Infectious_Diseases | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

May 21, 2019 / by / in
Comments